Parikh Anand Kiran 4/A

What Happened

• Anand K. Parikh, President & CEO and a director of Sensei Biotherapeutics (ticker FTH), received three awards of Series B Non‑Voting Convertible Preferred Stock on February 17, 2026. The reported award amounts were 761.428, 12,320 and 136,884 shares of Series B Preferred (derivative awards). Under the Certificate of Designation each Series B Preferred share is convertible into 1,000 shares of Sensei common stock — i.e., these preferred amounts correspond to approximately 761,428; 12,320,000; and 136,884,000 common‑share equivalents respectively. The awards were issued in connection with the closing of a merger and exchanges of HoldCo common stock and option awards (see footnotes).

Key Details

• Transaction date: February 17, 2026. Report amended: filed June 16, 2026 to correct previously reported counts (original Form 4 filed Feb 19, 2026).
• Price: N/A (derivative/award; no open‑market trade or cash purchase/sale reported).
• Reported awards (Series B Preferred shares): 761.428; 12,320; 136,884.
• Common‑share equivalent (per F1: 1 Series B Preferred = 1,000 Common): ≈761,428; 12,320,000; 136,884,000 common shares respectively.
• Why issued: per footnotes, awards were received in exchange for HoldCo common stock under the Merger Agreement and for certain Faeth (HoldCo) option awards converted in the merger.
• Vesting: some awards are subject to vesting schedules — e.g., earlier option awards vest monthly over 48 months beginning Aug 1, 2022 (F5); another tranche vests monthly beginning Mar 1, 2026 through Jan 1, 2027 with remaining balance vesting Feb 1, 2027 (F7).
• Shares owned after transaction: not specified in this Form 4 amendment.
• Filing note: This is an amended Form 4 correcting previously reported option and preferred share counts.

Context

• These entries are derivative awards tied to a corporate merger and option conversions, not open‑market buys or sales. Because Series B Preferred shares are convertible into large numbers of common shares (1,000:1), the reported preferred‑share counts translate into large common‑share equivalents — but many shares may be subject to vesting and conversion conditions. The amendment simply corrects previously reported quantities; it does not by itself indicate a buy/sell trading signal.